ARQ-255 is under clinical development by Arcutis Biotherapeutics and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARQ-255’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARQ-255 overview
ARQ-255 is under development for the treatment of alopecia areata. It is administered by topical route as suspension. The drug candidate is an alternate formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation. It acts by targeting JAK1 (Janus Kinase 1).
Arcutis Biotherapeutics overview
Arcutis Biotherapeutics (Arcutis) is a biopharmaceutical company. It is focused on developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. The company’s pipeline products include ARQ-151, a topical roflumilast cream for treating plaque psoriasis and atopic dermatitis (eczema); ARQ-154, a topical roflumilast foam against seborrheic dermatitis and scalp psoriasis; ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. It is investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
For a complete picture of ARQ-255’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
